Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya

Key facts

Sponsor

KNCV Tuberculosis Foundation

Principal Investigator

Jeremy M Chakaya, MD

Centre for Respiratory Diseases Research, Kenya Medical Research Institute

Intervention

community IPT(other)

Enrollment

1259 enrolled

Eligibility

15 years · All sexes

Timeline

2009 – 2012

Study locations (18)

• Makuyu H/C, Makuyu-Muranga, Central, Kenya
• Huruma Lions -Central district, Nairobi, Nairobi North, Kenya
• Kangemi HC, Nairobi, Nairobi North, Kenya
• Blue House, Mathare, Nairobi, Nairobi South, Kenya
• Jericho HC, Nairobi, Nairobi South, Kenya
• Kibera AMREF, Nairobi, Nairobi South, Kenya
• MMM, Mukuru, Embakasi, Nairobi, Nairobi South, Kenya
• Pumwani Majengo H/C, Nairobi, Nairobi South, Kenya
• Remand H/C, Nairobi, Nairobi South, Kenya
• Soweto Kayole, Embakasi, Nairobi, Nairobi South, Kenya
• KAPSABET District Hospital, Kapsabet-Nandi, North Rift, Kenya
• NYALENDA, Kisumu District, Nyanza North, Kenya
• Kadem leprosy, Migori, Migori District, Nyanza South, Kenya
• Muhuru Health centre, Migori, Migori District, Nyanza South, Kenya
• Awendo SDH, Rongo District, Nyanza South, Kenya
• +3 more locations on ClinicalTrials.gov

Collaborators

Stichting Mondiale Tuberculose (SMT) · Kenya Medical Research Institute · Division of Leprosy Tuberculosis and Lung Disease, MOPHS, Kenya · Centres for Disease Control and Prevention, Kenya. · Ministry of Public Health and Sanitation, Kenya · Kenya National AIDS & STI Control Programme

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07164742
  Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)
  Johns Hopkins University
• RECRUITINGNCT07077213
  18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
  Children's Hospital Medical Center, Cincinnati
• RECRUITINGNCT07451899
  TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease
  Universitas Padjadjaran
• RECRUITINGNCT06845618
  Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment
  University of Oxford
• ENROLLING BY INVITATIONNANCT06984887
  Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
  Mercy Corps Pakistan
• RECRUITINGNCT07018076
  Candidate Clinical Correlate of Prognostic Outcome for TB Study
  University of California, San Francisco
• RECRUITINGNANCT07271225
  Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting
  Indonesia University
• RECRUITINGNCT06585358
  DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis
  Karolinska Institutet

See all trials for Tuberculosis →